Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders

C. Okhuysen-Pfeiffer 1,2,43, M. Z. van der Horst 1,2,3,43, C. A. Bousman 4,5,6,7,43, B. Lin 1,2,43, K. R. van Eijk 2, S. Ripke 8, Y. Ayhan 9, M. O. Babaoglu 10, M. Bak 11,12, W. Alink 13, H. van Beeck 14, E. Beld 15, A. Bouhuis 16, M. Edlinger 17, I. M. Erdogan 9, A. Ertuğrul 9, G. Yoca 9,18, I. P. Everall 7,19, T. Görlitz 20,21, GROUP (Genetic Risk and Outcome of Psychosis) investigators*, K. P. Grootens 22,23, S. Gutwinski 8,30, E. Repo-Tiihonen 24, T. Oviedo-Salcedo 20, J. Schneider-Thoma 28, S. Schreiter 8,30, H. Tuppurainen 24, M. Veereschild 3, S. Veerman 31, M. de Vos 3, E. Wagner 4, C. Pantelis 1,2,43, M. Z. van der Horst, C. A. Bousman, B. Lin. *A list of authors and their affiliations appears at the end of the paper.

© The Author(s) 2022

Clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia. However, response is highly variable and possible genetic underpinnings of this variability remain unknown. Here, we performed polygenic risk score (PRS) analyses to estimate the amount of variance in symptom severity among clozapine-treated patients explained by PRSs (R2) and examined the association between symptom severity and genotype-predicted CYP1A2, CYP2D6, and CYP2C19 enzyme activity. Genome-wide association (GWA) analyses were performed to explore loci associated with symptom severity. A multicenter cohort of 804 patients (after quality control N = 684) with schizophrenia spectrum disorder treated with clozapine were cross-sectionally assessed using the Positive and Negative Syndrome Scale and/or the Clinical Global Impression-Severity (CGI-S) scale. GWA and PRS regression analyses were conducted. Genotype-predicted CYP1A2, CYP2D6, and CYP2C19 enzyme activities were calculated. Schizophrenia-PRS was most significantly and positively associated with low symptom severity (p = 1.03 × 10⁻³; R2 = 1.85). Cross-disorder-PRS was also positively associated with lower CGI-S score (p = 0.01; R2 = 0.81). Compared to the lowest tertile, patients in the highest schizophrenia-PRS tertile had 1.94 times (p = 6.8 × 10⁻⁸) increased probability of low symptom severity. Higher genotype-predicted CYP2C19 enzyme activity was independently associated with lower symptom severity (p = 8.44 × 10⁻³). While no locus surpassed the genome-wide significance threshold, rs1923778 within NFIB showed a suggestive association (p = 3.78 × 10⁻⁷) with symptom severity. We show that high schizophrenia-PRS and genotype-predicted CYP2C19 enzyme activity are independently associated with lower symptom severity among individuals treated with clozapine. Our findings open avenues for future pharmacogenomic projects investigating the potential of PRS and genotype-predicted CYP-activity in schizophrenia.
INTRODUCTION
About one-third of patients with schizophrenia is considered to have treatment-resistant schizophrenia (TRS) [1]. TRS has been defined as the persistence of symptoms despite at least two trials of antipsychotic medications of adequate dose and duration with documented adherence [2–4]. For patients with TRS, clozapine is the most effective antipsychotic drug [5, 6]. However, 40% of TRS-patients achieve no sufficient response to clozapine, suggesting that up to 20% of schizophrenia patients are ultra-resistant (defined as failure to respond to adequate trials of two antipsychotics and clozapine) [7]. Despite its efficacy, the mean delay in clozapine prescription reaches up to 9 years [8–10], which in turn is associated with poor treatment outcomes and less functional recovery [11, 12]. Elucidating determinants of symptom severity while on clozapine may contribute to early identification of those more likely to be responsive to clozapine, enabling patients to start clozapine earlier in their disease course, resulting in a better quality of life, increased life expectancy, and lower economic burden [13, 14]. This is all the more important given the evidence that clozapine as first- or second-line therapy is more effective than other antipsychotics [11, 15, 16]. In addition, patients who are less likely to be responsive to clozapine may delay clozapine treatment, avoiding unnecessary potential side effects and blood monitoring.

A promising strategy for the identification of genetic variation associated with symptom severity among clozapine users, is the genome-wide association study (GWAS) that also allows to generate data for polygenic risk scoring (PRS). Several GWAS have identified candidate loci for clozapine blood concentrations and severe adverse drug reactions associated with clozapine, but limited focus has been given to symptomatic outcomes in patients using clozapine [17–21]. To our knowledge, there has only been one study that used a genome-wide approach to examine clozapine treatment outcome [22]. In that study of 123 clozapine-treated individuals, no statistically significant differences in schizophrenia-PRS between responders and nonresponders were detected (N = 123, p = 0.06) [22], PRS analyses performed to uncover differences between responders and nonresponders of other antipsychotics have yielded inconsistent results [23–26].

Another promising approach that complements GWAS and PRS, is the examination of known haplotype variation in genes associated with clozapine metabolism. CYP1A2 is considered the primary metabolism pathway for clozapine with secondary minor contributions from CYP3A4/5, CYP2D6, and CYP2C19 that collectively produce two metabolites, norclozapine (active) and clozapine n-oxide (inactive) [27]. Although norclozapine possesses the hallmark characteristics of an atypical antipsychotic [28], it is thought to have low antipsychotic activity and may be responsible for side effects [29]. The role CYP enzymes play in clozapine metabolism can be exemplified by the comparison of clozapine blood concentrations of smokers and nonsmokers. The polycyclic aromatic hydrocarbons produced by smoking are established inducers of CYP1A2 enzymatic activity and smokers have consistently been shown to have lower clozapine and higher norclozapine blood concentrations compared to nonsmokers [30, 31]. Thus, the relationship between CYP enzyme activity and clozapine metabolism is notable, can differ between persons, and as a result, clozapine blood concentrations among individuals prescribed the same dose may vary. Because of this variation, therapeutic drug monitoring of clozapine blood concentrations is routinely applied. Previous studies have suggested that clozapine blood concentrations ≥350 ng/mL are associated with superior symptomatic outcome [32]. However, determining the required dose for an individual to achieve this target blood concentration and symptomatic relief can be challenging. As such, several studies have used haplotype variation in CYP1A2, CYP2C19, and CYP2D6 as markers of an individual’s capacity to metabolize clozapine and their probability of receiving symptomatic relief [33–36]. Although results of these studies have been inconsistent, recent findings suggest these inconsistencies could be a result of phenoconversion, a phenomenon in which an individual’s genotype-predicted drug metabolism does not reflect their observed metabolism, due to the presence of nongenetic factors such as concomitant medications (e.g., (es)citalopram) and smoking behavior [37]. Thus, we hypothesized that genotype-predicted drug metabolism corrected for phenoconversion would be associated with clozapine blood concentrations and symptom severity.

Given the lack of established knowledge about genetic mechanisms underlying clozapine treatment outcome, this is the first study in patients with severe schizophrenia that dissects associations between symptom severity and genome-wide data. An international team with a range of different backgrounds joined forces several years ago, resulting in a unique and the largest dataset of clozapine users with genome-wide and symptom severity data available. The aims of the study were to analyze the amount of variance in symptom severity among clozapine-treated patients explained by PRSs, to examine the association between symptom severity and genotype-predicted CYP1A2, CYP2D6, and CYP2C19 enzyme activity, and explore loci associated with symptom severity using GWA analyses.

PARTICIPANTS AND METHODS
Participants
Participants (N = 804) came from five independent cohorts: 470 participants were recruited by the Clozapine International (CLOZIN) [38–41] consortium in the Netherlands, Germany, Austria, and Finland; 174 participants by the Genetic Risk and Outcome of Psychosis (GROUP) consortium in the Netherlands; 80 participants by the Cooperative Research Centre (CRC) in Australia; 50 participants by Hacettepe University in Turkey; and 30 participants by Mental Health Services Rivierduinen in the Netherlands. All studies were approved by their respective local Institutional Review Boards and all participants provided written informed consent prior to participation. The studies were compliant with the Declaration of Helsinki (2013) [42]. Participants were included if they: (1) were aged 18 years or older, (2) had a diagnosis of schizophrenia spectrum disorder (SSD), and (3) were using clozapine (no minimum duration of treatment). The eligibility criteria were not strict to represent ‘real world’ patients, as this is valuable for clinical value and applicability. Clozapine blood levels were measured in local accredited laboratories, ~12 h after the last clozapine dose intake. More information about each cohort is provided in the Supplementary Methods.

Phenotyping
Symptom severity was assessed by treating physicians or trained study raters using the Clinical Global Impression-Severity (CGI-S) scale and/or the Positive and Negative Syndrome Scale (PANSS) [43, 44]. CGI-S scores were available for participants from CLOZIN, Hacettepe University, and Mental Health Services Rivierduinen, and PANSS scores for participants from GROUP and CRC Australia. Previous studies have shown a correlation between PANSS scores, Brief Psychiatric Rating Scale (BPRS) scores, and CGI-scores and the authors of these studies provided us with a table to convert PANSS scores to CGI-S scores (Supplementary Table 1) [45, 46]. Our main outcome was symptom severity defined as a quantitative measure (CGI-S score) and our secondary outcome was symptom severity defined as a binary measure (low vs. high symptom severity). Low symptom severity corresponded to a (converted) CGI-S score of 1 to 3 (‘normal to mildly ill’) and high symptom severity corresponded to a (converted) CGI-S score of 4 to 7 (‘moderately ill’ to ‘among the most extremely ill patients’). See Supplementary Methods for more detailed information.

Genotyping and quality control
Genotyping and quality control followed standard procedures and are described in Supplementary Methods.

Statistical analysis
Genome-wide association analyses. Statistical analyses were conducted using PLINK v1.90b3z 64-bit and R version 3.2.2 (14 Aug 2015; http://www.
r-project.org/) software packages. Exploratory GWAS was conducted using linear regression for quantitative outcome and logistic regression for binary outcome. The quantitative outcome analysis was thus a quantitative trait locus (QTL) analysis, conducted similarly to previously reported [47, 48]. However, to evaluate the robustness of our findings, as sensitivity analyses, we repeated all analyses after removing participants deviating more than 3 standard deviations (SD) from the means of the first four PCs, based on the HapMap3 HRC r1.1 2016 (GRCh37/hg19) population (N = 1397; Supplementary Fig. 1). Genome-wide significance was set at $p < 5 \times 10^{-8}$ and suggestive significance at $p < 5 \times 10^{-5}$.

Post-GWAS analysis was performed for identification and annotation of independent associations within our data, using Functional Mapping and Annotation of genetic associations (FUMA) [50] and Hi-C coupled Multi-marker Analysis of GenoMic Annotation (H-MAGMA v1.08; Supplementary Methods) [51].

**Polygenic risk score analyses.** PRS is an estimate of an individual’s polygenic liability to a certain trait [52]. PRSs were calculated for the following three traits relevant for schizophrenia or clozapine metabolism, using the most recent GWAS’ summary statistics: schizophrenia [53], cross-disorder [54], and clozapine metabolism [17]. The PRSs were corrected for sex, age, and 10 PCs, and the Bonferroni-corrected significance level was $p < 0.017$ (see Supplementary Methods and Supplementary Table 2 for details).

**Genotype-predicted enzyme activity score analysis.** Multiple drug metabolizing enzymes contribute to the demethylation and oxidation of clozapine (physiologically active compound) to N-desmethylclozapine ("norclozapine"; putatively active metabolite) and clozapine n-oxide (considered to be an inactive metabolite) [27, 55, 56]. However, CYP1A2, and to a lesser extent CYP2C19 and CYP2D6, are considered the primary clozapine metabolizing enzymes in vivo [27]. Imputed genotype data (see ‘Genotyping—Genotyping and quality control’ was subjected to Stargazer v1.08 [57] to call CYP-haplotypes (star alleles). Activity scores for CYP2D6 were based on translation tables maintained by the Pharmacogene Variation (PharmVar) Consortium [58] and the Pharmacogenomics Knowledgebase (PharmGKB), whereas activity scores for CYP1A2 and CYP2C19 followed previously published scoring methods (Supplementary Methods and Supplementary Table 4) [59–61].

Prior to analysis, CYP-activity scores were corrected for concomitant inhibitors or inducers of each of the corresponding genes using previously employed phenoconversion methodology (Supplementary Methods and Supplementary Table 5) [37]. To determine if CYP-activity scores were associated with symptom severity outcomes, logistic and linear regression models were fitted, with age, sex, dose-adjusted clozapine levels (i.e., concentration-to-dose ratio, one measurement per participant), and duration of clozapine therapy included as covariates [37]. In addition, linear regression models were fitted to estimate the amount of variance in dose-adjusted clozapine levels that was explained by CYP2C19, CYP1A2, and CYP2D6. Levels of N-desmethylclozapine were unavailable. The Bonferroni-corrected significance level was $p < 0.017$, as we corrected for three independent regression analyses performed.

In the event of detection of significant associations between symptom severity on the one and PRS as well as CYP genotypes on the other hand, we hypothesized these were independent and therefore tested whether this was indeed the case by adding the significant PRS(s) to the model.

**RESULTS**

**Genome-wide association analysis**

Six hundred and eight-four individuals and 5,506,411 SNPs passed the QC and were included in the GWAS. There were 330 participants with low and 354 with high symptom severity (see Supplementary Table 6 for demographic and clinical characteristics). Linkage disequilibrium (LD)-intercept scores and genomic inflation correction factors (λGC) pre- and postimputation were all <1.02, suggesting no inflation of the test statistics (Supplementary Fig. 2).

No genome-wide significant hits were identified. The most significantly associated locus was detected between quantitative outcome and intronic rs1923778 on chromosome 9 ($p = 3.78 \times 10^{-7}$; Fig. 1A, Supplementary Fig. 3A & Supplementary Table 6; Fig. 1B, Supplementary Fig. 3B & Supplementary Table 7), within *nuclear factor 1 B-type* (NFIB). We did not detect dose-adjusted clozapine level differences between genotype groups at this locus, rendering it unlikely that the association we found is merely a proxy for association with dose-adjusted clozapine levels (Supplementary Fig. 4 & Supplementary Table 8). The most significant locus for binary outcome was intronic rs4742565s on chromosome 9 ($p = 1.64 \times 10^{-6}$; Fig. 1B, Supplementary Fig. 3B).

![Fig. 1 Genome-wide association analysis of symptom severity while on clozapine. A, B Manhattan plots depicting the genome-wide association results of symptom severity while on clozapine for quantitative and binary outcome. The X-axis shows the chromosomal positions. The Y-axis shows $-\log 10$ (p values). The red line illustrates the genome-wide significance level of $p = 5 \times 10^{-8}$, and the blue line illustrates the suggestive level of significance of $p = 5 \times 10^{-5}$. The arrows indicate the top loci and the closest genes.](image-url)
**Polygenic risk score analysis**

The same 684 individuals were included in PRS-analyses. Schizophrenia-PRS was significantly associated with binary outcome ($p = 1.03 \times 10^{-3}, R^2 = 1.85, p_{\text{adj}} = 0.4$, Figs. 2A and 3A). Patients in the highest schizophrenia-PRS tertile had 1.94 times ($p = 6.84 \times 10^{-4}$; 95% confidence interval (CI) = 1.33--2.81) increased chances of low symptom severity while on clozapine compared to patients in the lowest schizophrenia-PRS tertile (Fig. 2B, Supplementary Table 9 and Supplementary Table 10). Similarly, patients in the highest schizophrenia-PRS decile had 2.26 times ($p = 3.96 \times 10^{-3}, 95\% \text{ CI} = 1.30--3.91$) increased chances of low symptom severity while on clozapine compared to patients in the lowest schizophrenia-PRS decile (Fig. 2B, Supplementary Table 9 and Supplementary Table 10). Cross-disorder-PRS was significantly associated with quantitative outcome ($p = 0.01, R^2 = 0.81, p_{\text{adj}} = 0.3$, Fig. 3B). Other PRS association results were not significant (Supplementary Results, Supplementary Fig. 7A–F). In sensitivity analyses results remained similar (Supplementary Results).

**Genotype-predicted enzyme activity score analyses**

Higher CYP2C19 activity score was significantly associated with greater probability of low symptom severity (i.e., symptom improvement) (odds ratio (OR) = 1.59, 95% CI = 1.13--2.24, $p = 8.51 \times 10^{-3}$, Supplementary Table 14), schizophrenia-PRS and the first 10 PCs (OR = 1.63, 95% CI = 1.97--2.43, $p = 0.02$, Supplementary Table 15), or the top two GWAS hits (NFIB rs1923778, PTPRD rs4742565) (OR = 1.60, 95% CI = 1.06--2.42, $p = 0.02$, Supplementary Table 16).

CYP1A2 activity score was not associated with our binary (Fig. 4D) or quantitative (Fig. 4E) outcomes but was inversely correlated with dose-adjusted clozapine levels ($p = -0.35, p = 2.71 \times 10^{-10}$; Supplementary Table 13, Fig. 4F). CYP2D6 activity score was not associated with either symptom severity or dose-adjusted clozapine levels (Fig. 4G–I). Neither NFIB rs1923778 ($beta = -0.08, p = 0.47$ nor PTPRD rs4742565 ($beta = 0.07, p = 0.26$) were associated with dose-adjusted clozapine levels. No interaction between CYP2C19 and schizophrenia-PRS was found for binary outcome ($beta = 0.04, p = 0.17$). It is important to note that the C/D ratios were significantly higher in the Hacetette cohort, compared to the other cohorts (Supplementary Table 8). In sensitivity analyses results remained similar, indicating that ancestry does not influence the results and conclusions (Supplementary Results). Furthermore, there was no difference in the dose-adjusted clozapine concentrations between people with low symptom severity (mean = 1.37, SD = 0.86) and high symptom severity (mean = 1.42, SD = 0.91; $t = 0.57$, $p = 0.57$; Supplementary Results, Supplementary Table 17&18, Supplementary Fig. 13) or in absolute clozapine concentrations between people with low symptom severity (mean = 426.35, SD = 261.12) and high symptom severity (mean = 421.67, SD = 239.30; $t = -0.17$, $p = 0.88$; Supplementary Fig. 13).

**DISCUSSION**

To our knowledge, this is the first study using a comprehensive, genome-wide approach to examine the genomic underpinnings of symptom severity among individuals with SSD treated with clozapine ($N = 804$ before and $N = 684$ after QC). Using a novel approach of integrating genome-wide, PRS, and CYP analyses, we demonstrate that higher schizophrenia-PRS and higher genotype-predicted CYP2C19 enzyme activity are independently associated with lower symptom severity while on clozapine.

Although no significant genome-wide hit was discovered, the loci on NFIB (rs1923778, $p = 3.78 \times 10^{-7}$) and PTPRD (rs4742565, $p = 1.64 \times 10^{-4}$) are of interest given previous literature. NFIB is a protein-coding gene associated with embryonic development,
Fig. 3  Violin plots displaying the distribution in symptom severity while on clozapine by polygenic risk score subgroups. A, B Violin plots of schizophrenia-PRS (PRS-SCZ) comparison for binary outcome, and cross-disorder-PRS (PRS-CDG) tertile comparison for quantitative outcome. For both analyses the best fitting \( p \) was used. The dashed line illustrates the mean PRS-SCZ (A) and the mean residual CGI-S score (B) in all participants. Differences were determined by linear regression of quantitative outcome on PRS tertile and using a \( T \)-test for binary outcome, corrected for sex, age, and 10 PCs (Supplementary Methods). **\( p < 5.0 \times 10^{-3} \). ns nonsignificant.

Fig. 4  Association between CYP-activity scores, symptom severity while on clozapine and dose-adjusted clozapine levels. A–I. Association of corrected CYP2C19, CYP1A2, and CYP2D6 genotype-predicted activity scores with symptom severity while on clozapine and dose-adjusted clozapine levels.
The tumor growth, and brain development [62]. A recent GWAS of clozapine levels found a different locus on NFIB (rs28379954; Supplementary Table 19) to be associated with clozapine levels \( \left( p = 1.68 \times 10^{-6} \right) \) and risk of subtherapeutic serum concentrations [17]. Moreover, NFIB expression is correlated with clinical improvement in depressed patients treated with citalopram, suggesting it could be of interest for pharmacogenomic studies in psychiatry more broadly than merely for antidepressants [63]. PTPRD is a protein-coding gene that is highly expressed in the brain and that plays a role in synaptic adhesion and organization and has been shown to regulate neurogenesis in mice [64]. Several studies have shown that PTPRD has both an oligogenic and a polygenic contribution of common and rare variations in neurological, behavioral and neurodevelopmental disorders and was found to be associated with schizophrenia spectrum disorder, obsessive-compulsive disorder, and substance use disorders [64–69]. No previous association between PTPRD and clozapine has been reported, but two recent GWASs found PTPRD to be associated with antipsychotic-induced weight gain \( \left( p = 9.26 \times 10^{-9} \right) \) [70] and suggestively associated with response to the atypical antipsychotic lurasidone in European and African participants \( \left( p = 6.03 \times 10^{-5} \right. \text{ and } p = 4.29 \times 10^{-5} \), respectively) [23].

Our PRS analyses revealed that higher schizophrenia-PRS was associated with lower symptom severity as a binary trait and that higher cross-disorder-PRS was associated with lower symptom severity as a quantitative trait. To our knowledge, no previous study has examined the association between cross-disorder-PRS and antipsychotic treatment outcome. However, several studies have evaluated the association between schizophrenia-PRS and antipsychotic treatment outcome [22–26], although only one of these studies examined clozapine response [22]. In line with our results, that study reported higher schizophrenia-PRS in clozapine responders compared to clozapine nonresponders, although this was not significant \( \left( p = 0.06 \right) \) [22]. Differences in phenotyping (here we used PANSS and CGI-S scales; in the previous study a nonvalidated, 4-level ordinal scale was used) and power \( \left( N = 684 \text{ vs. } N = 123 \right) \) possibly explain differences in statistical significance \( \left( p = 1.03 \times 10^{-14} \text{ vs. } p = 0.06 \right) \). The same direction of association was found in a GWAS of lurasidone response \( \left( N = 429 \right) \) [23] and a risperidone response GWAS [24]. However, a study with first-episode psychosis patients using several antipsychotics (but not clozapine) found that higher schizophrenia-PRS was associated with lower response rates (i.e. higher symptom severity) [71]. Several studies indicate that schizophrenia-PRS increases when comparing first-episode psychosis to schizophrenia, and schizophrenia to TRS [22, 71–73], although there is also conflicting evidence for the latter [74, 75]. Bearing those former observations in mind, higher schizophrenia-PRS may characterize a subset of TRS-patients more likely to respond well to clozapine. Speculatively, people with low schizophrenia-PRS may thus have a better prognosis with shorter duration of illness, whereas in advanced stages of illness those with high schizophrenia-PRS may respond better to clozapine [73]. Alternatively, it is also plausible that people with higher schizophrenia-PRS are genetically more close to schizophrenia and therefore more responsive to clozapine, while people who are more genetically distant and/or where other environmental factors exert an influence are less responsive to clozapine.

Furthermore, we found a positive association between genotype-predicted CYP2C19 enzyme activity and symptom severity. This finding aligns with a previous study of 137 clozapine-treated patients that reported CYP2C19 ultrarapid metabolizers \( \left( ^{*}17/17 \right) \) were five times more likely to show clinical improvements [76], although smaller studies have shown no association [37, 77] or an inverse association [78] between CYP2C19*17 carriers and clozapine-related symptomatic outcomes. Although CYP2C19 is involved in the demethylation of clozapine to N-desmethyclozapine, a pharmacologically active metabolite that binds to an array of receptors including dopamine D2 and D3 receptors, muscarinic receptors and serotonergic receptors [27], current evidence suggests CYP2C19 genetic variation has limited effect on clozapine metabolism [37, 79, 80]. As such, the association between CYP2C19 enzymatic activity and improvement in clinical outcome is unlikely to be explained by differential clozapine blood concentrations. In fact, we did not detect an association between CYP2C19 enzyme activity and clozapine concentrations. Alternatively, our findings may reflect CYP2C19’s role in metabolizing endogenous compounds in the brain [81]. Human studies have shown increased CYP2C19 genotype-predicted activity was associated with smaller hippocampi volumes and greater suicidality [82], although attempts to replicate these associations have been unsuccessful [83]. A weakness of our study is the lack of a replication cohort and consequently our findings await replication in larger datasets with diverse ancestries to more firmly guard against the risk of type-I error that is inherent in research projects (such as ours) where several statistical tests are performed. Therefore, future investigations of the relationships between genotype-predicted CYP2C19 enzyme activity and symptomatic outcomes are warranted. In such future studies, norclozapine should also be taken into account to allow a separate genetic study on such levels and ratios with clozapine. Additionally, it is interesting that in the current study no association between CYP1A2 and symptom severity is found, as this was suggested from a previous study [37]. Perhaps this difference in findings is explained by the use of different measurements of symptom severity, as the previous study used PANSS [37], while the current study used CGI-S which is less specifically about psychotic symptoms. It is good to note, there is still little understanding of the relationship between CYP1A2 and symptom severity, and this should be investigated in more detail.

Strengths of our study include our unique sample of over 800 multiethnic patients with SSD using clozapine, and the use of a very recent GWAS-platform, and genotype-predicted activity of relevant metabolizing enzymes. Furthermore, although no longitudinal data on clozapine response rates was available for our participants, the distribution of low and high symptom severity while on clozapine in our cohort \( \left( N = 330 \text{ vs. } N = 354 \right) \) aligns with reported response rates to clozapine [7]. Nonetheless, several limitations should be considered when interpreting our results. First, the main limitation is that our phenotype, symptom severity, was assessed cross-sectionally and therefore no distinction can be made between clozapine response and individual variability in disease severity. In general, patients starting clozapine have a fairly severe disease course with high symptom severity prior to initiation of treatment. However, there is a high degree of heterogeneity in symptom severity in this population and data on symptom severity prior to initiation of clozapine was lacking, so the results of the GWAS should be interpreted in light of this limitation. Second, participants were cross-sectionally ascertained using two symptom scales, which made the use of a conversion table necessary. The lack of inflation of our GWAS test statistic as well as the consistency between the results of the main and sensitivity analyses’ nonetheless support the robustness of the results. Third, our study population is derived from multiple cohorts and not all covariate data was complete for all cohorts. For future GWASs, it would be highly interesting to perform subgroup analyses on patients stopping clozapine due to poor clinical effect, as this could provide highly valuable genetic information on ultra-TRS, and to examine the effects of possible gender differences, previous antipsychotic medication, and concomitant therapies. We are also currently working on a genome-wide meta-analysis of clozapine blood levels to further elucidate possible genetic underlying mechanisms of the interindividual variability in...
clozapine concentrations. In the meantime, the recruitment of clozapine users for the CLOZIN study is still ongoing, so that we can perform a more powerful GWAS in the near future. This larger sample size is also needed to be able to detect associations between single SNPs within CYP enzymes and clozapine concentrations, as we lacked statistical power to do so. Fourth, we estimate that about 3% of our cohort were incorrectly classified as CYP2D6 normal metabolizers due to the absence of copy number variation data required to detect CYP2D6 ultrarapid metabolizers (Supplementary Methods). However, to our knowledge, there is no evidence suggesting this misclassification error would have a meaningful impact on our study findings. Fifth, as the GROUP cohort is an older cohort, there might be sample overlap between the current and the PGC-schizophrenia study population and consequently the PGC-cross-disorder study population. We therefore repeated our analyses excluding the samples from GROUP: all PRS association patterns remained similar with the same p values albeit less significant, as expected due to loss of power (Supplementary Fig. 9A, B). Furthermore, there were no clozapine concentrations available from GROUP. Therefore, this cohort was not represented in the CYP analyses. Another limitation is that we could not definitively determine for all cohorts whether clozapine concentrations represented steady state and trough levels nor could we verify adherence. Nonetheless, as our observed clozapine C/D ratios follow the expected pattern of steady-state and trough levels (Supplementary Fig. 14A–D), it is likely that these levels are reliable approximations. Inflammation (e.g., C-reactive protein) and caffeine consumption data, which can inhibit CYP1A2 activity, were not available and could therefore be over-estimated for some participants. Finally, caution in the interpretation of our GWAS results is warranted given the lack of a replication cohort.

In conclusion, we demonstrate for the first time that higher schizophrenia-PRS and CYP2C19 predicted activity are independently associated with low symptom severity among clozapine-treated schizophrenia patients. For future clinical translation, if these findings are replicated, schizophrenia-PRS and genotype-predicted CYP2C19 activity may be used in conjunction with nongenetic factors to help predict clozapine response, ultimately allowing early identification of individuals more likely responding to clozapine. Such future studies should also incorporate deeper phenotyping information collected (e.g., clinical symptomatology in further detail, steady-state clozapine levels, adherence) in a longitudinal design. Timely prescribing may improve patients’ prognosis, given clozapine’s superiority over other antipsychotics in early disease stages [15].

REFERENCES

1. Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: A review. Br Med Bull. 2015;114:169–79.
2. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017;174:216–29.
3. Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64:5–19.
4. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The schizophrenia patient outcomes research team (PORT): Updated treatment recommendations 2009. Schizophr Bull. 2010;36:94–103.
5. Luyke JJ, Stam N, Tanskanen A, Tihonen J, Taipale H. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. Br J Psychiatry. 2020;207:498–505.
6. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206–27.
7. Siskind D, Siskind V, Kisely S. Clozapine Response Rates Among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Can J Psychiatry. 2017;62:772–7.
8. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: A case note review. J Clin Psychiatry. 2003;64:30–34.
9. Doyle R, Behan C, O’Keeffe D, Masterson S, Kinsella A, Kelly A, et al. Clozapine Use in Psychosis. J Clin Psychopharmacol. 2017;37:512–7.
10. Howes OD, Vergunft F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: Study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201:481–5.
11. Shah P, Iwata Y, Piltman E, Brown EE, Caravaggio F, Kim J, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. J Clin Psychopharmacol. 2017;37:214–22.
12. John AP, Ko EK, Dominic A. Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern. Can J Psychiatry. 2018;63:526–31.
13. Jin H, Tappenden P, MacCabe JH, Robinson S, McCRone P, Byford S and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendations. Br J Psychiatry. 2020;6:1–6.
14. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Corell CU, de Haan L. Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years. Schizophr Bull. 2019;45:315–29.
15. Okhuijsen-Pfeifer C, Huisman EAH, Hasan A, Sommer IEC, Leucht S, Kahn RS, et al. Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand. 2018;138:281–8.
16. Siskind D, McCutcheon R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209:385–92.
17. Smith RL, O’Connell K, Athanasiou L, Djurovic S, Krkening MK, Andreassen OA, et al. Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients–a genome-wide association study adjusting for smoking habits. Transl Psychiatry. 2020;10:198.
18. Pardinas AF, Nalmpantzi M, Pocklington AJ, Legge SE, Medway C, King A, et al. Pharmacogenomic Varians and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism. Am J Psychiatry. 2019;176:477–86.
19. de With SAJ, Pultil SL, Staal WG, Kahn RS, Ophoff RA. More than 25 years of genetic studies of clozapine-induced agranulocytosis. Pharmacogenomics J. 2017;17:304–11.
20. Legge SE, Hamshere ML, Ripke S, Pardinas AF, Goldstein JL, Rees E, et al. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Mol Psychiatry. 2018;23:162–3.
21. Legge SE, Pardinas AF, Helhuis M, Jansen JA, Kollie K, Knapper S, et al. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Mol Psychiatry. 2019;24:328–37.
22. Frank J, Lang M, Witt SH, Strohmaier J, Rujescu D, Cichon S, et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Mol Psychiatry. 2015. https://doi.org/10.1038/mp.2014.56.
23. Li J, Yoshikawa A, Brennan MD, Ramsey TL, Meltzer HY. Genetic predictors of antipsychotic response to lurasidone identified in a genome-wide association study and by schizophrenia risk genes. Schizophr Res. 2018;192:187–92.
24. Santoro ML, Ota V, de Jong S, Noto C, Spiンドola LM, Talarico F, et al. Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort. Transl Psychiatry. 2018;8:174.
25. Amare AT, Schubert KO, Hou L, Clark SR, Papel S, Heilbronner U, et al. Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. JAMA Psychiatry. 2018;75:65–74.
26. Zhang J-P, Robinson D, Yu J, Gallego J, Fleischhacker WW, Kahn RS, et al. Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. Am J Psychiatry. 2019;176:21–28.
27. Thorn CF, Muller DJ, Altman RB, Klein TE. PharmGRB summary: clozapine path- way, pharmacokinetics. Pharmacogenet Genomics. 2018;28:214–22.
28. Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhauw DS, Pharmacology of N-desmethylclozapine. Pharm Ther. 2007;115:223–31.
29. Mendoza MC, Lindenmayer JP. N-desmethylclozapine: is there evidence for its antipsychotic potential? Clin Neuropharmacol. 2009;32:154–7.
30. Seppälä NH, Leinonen EV, Lehtonen ML, Kivistö KT. Clozapine serum con- centrations are lower in smoking than in non-smoking schizophrenic patients. Pharm Toxicol. 1999;85:244–6.
31. Meyer JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol. 2001;21:569–74.
32. Wagner E, Kane JM, Corell CU, Howes O, Siskind D, Honer WG, et al. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment
8. Wagner E, Oviedo-Salcedo T, Pelzer N, Strube W, Mraus I, Gutwinski S, et al. Effects of Smoking Status on Remission and Memetic and Cognitive Outcomes in Schizophrenia Patients Treated with Clozapine. Psychopharmacology. 2020;253:273–83.

9. Okhuijsen-Pfeifer C, Ayhan Y, Lin BD, van Eijk KR, Bekema E, Kool LJGB, et al. Genetic Susceptibility to Clozapine-Induced Agranulocytosis/Neutropenia Across Ethnicities: Results From a New Cohort of Turkish and Other Caucasian Participants, and Meta-Analysis. Schizophr Bull. 2020. https://doi.org/10.1093/schbul/sbaa024.

10. Okhuijsen-Pfeifer C, Cohen D, Bogers JPAM, de Vos CMH, Hujsmiss EAH, Kahn RS, et al. Differences between physicians’ and nurse practitioners’ viewpoints on reasons for clozapine underprescription. Brain Behav. 2019;9:e1318.

11. Huismans R, Okhuijsen-Pfeifer C, Mulder EYH, Jongkind A, Cohen D, Bogers, JPAM, [Validatie van de Nederlandstalige Glasgow Antipsychotic Bijwerkingen Schaal voor Clozapine], Tijdschr Psychiatr. Published online 2020.

12. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 64th WMA General Assembly, Fortaleza, Brazil 2013;2013.

13. Kay SR, Fiszbein A, Opier LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.

14. National Institute of Mental Health. CGI. Global Clinical Impression. Psychiatry Psychiatry J World Fed Soc Biol Psychiatry. 2017;18:521–7.

15. Leucht S, Kane JM, Etschel E, Kissing L, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology. 2006;31:2318–25.

16. Leucht S, Rotte P, Davis JM, Engel RR. Equiperasitie link between the BPRS and the PANSS. Eur Neuropsychopharmacol. 2013;23:956–9.

17. Luykx JJ, Bakker SC, Visser WF, Verhoeven-Duff N, Buizer-Voskamp JE, de Heijer CL. Polymorphic expression of CYP2C19, and CYP2D6 genotype- and phenocconversion-predicted enzyme activity on clozapine exposure and symptom severity. Pharmacogenomics. 2020;2020;192–201.

18. Lee S-B, Wheeler MM, Thummel KE, Nickerson DA. Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences. Clin Pharm Ther. 2019;106:1328–37.

19. Lee S-B, Wheeler MM, Thummel KE, Nickerson DA. Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences. Clin Pharm Ther. 2019;106:1328–37.

20. Lee S-B, Wheeler MM, Thummel KE, Nickerson DA. Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences. Clin Pharm Ther. 2019;106:1328–37.

21. Lee S-B, Wheeler MM, Thummel KE, Nickerson DA. Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences. Clin Pharm Ther. 2019;106:1328–37.

22. Lee S-B, Wheeler MM, Thummel KE, Nickerson DA. Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences. Clin Pharm Ther. 2019;106:1328–37.
cognition, risk for depression and suicide: the search for the endogenous substrates. Pharmacogenomics. 2014;15:1841–4.

83. Savadlou A, Amanatkevicius A, Tiegó J, Haiw Z, Bellgrove MA, Fonimo A, et al. Impact of CYP2C19 genotype-predicted enzyme activity on hippocampal volume, anxiety, and depression. Psychiatry Res. 2020;288:112984.

Acknowledgements

We would like to thank R.L. Cummins, R. Kahn, M.K. Bakker, E. Bekema, H. Gismon, A. Jongkind and P. Kleymann for their valuable input (see Supplementary Acknowledgements for details). Dr. Bousman reports a grant from Alberta Innovates Strategic Research Project G2018000868, during the conduct of the study. Dr. Pardiñas' work is supported by a “Springboard” award by the Academy of Medical Sciences (SBF005 1083). Dr Luykx' work is supported by a personal grant from the Rudolf Magnus Young Talent Fellowship program of the University Medical Center Utrecht.

Author Contributions

COP, MH, CB and JL contributed to conception, design and methodology. COP, MH, KE, SR, YA, MB, MB, WA, HB, EB, AB, ME, IE, AE, GY, IE, TG, GROUP, KG, SG, TH, EJL, MK, ML, SL, SL, CM, AM, CP, AP, TOS, JST, SS, ERT, HT, MV, SV, MV, EW, DC, JB, JW, AAY, JT and AH contributed to data acquisition and pre-processing. COP, MH, CB, BL and AN analyzed the data. COP, MH, CB and J. drafted the manuscript. SR, YA, MB, MB, WA, HB, EB, AB, ME, IE, AE, GY, IE, TG, GROUP, KG, SG, TH, EJL, MK, ML, SL, SL, CM, AM, CP, AP, TOS, JST, SS, ERT, HT, MV, SV, MV, EW, DC, JB, JW, AAY, JT and AH participated in revising the manuscript critically for important intellectual content.

Competing Interests

Dr. Bousman reports he has received in-kind testing kits from Myriad Neuroscience, CNSDose, Genomind, and AB-Biotics for research purposes but has not received payments or received any equity, stocks, or options in these companies or any other pharmacogenetic companies. Dr. Lähteenvuo reports being a shareholder and board member at Genomi Solutions Ltd and Nursie Health Ltd; receiving research grants or awards from the Finnish Medical Foundation and Emil Aaltonen Foundation; receiving travel grants or speakers' awards from the Finnish Medical Foundation and Emil Aaltonen Foundation; and being a member at Genomi Solutions Ltd and Nursie Health Ltd; receiving research grants or awards from the Finnish Medical Foundation and Emil Aaltonen Foundation.

Group (Genetic Risk and Outcome of Psychosis) Investigators

T. van Amelsvoort36, A. A. Bartels-Velthuis11, R. Bruggeman37, W. Cahn1, S. Guloksuz11,38, L. de Haan25,26, R. S. Kahn1,39, F. Schirmbeck25,26, C. J. P. Simon11, J. van Os1, B. Z. Alizadeh40,41, J. J. Luykx1,2,3, B. P. F. Rutten11 and R. van Winkel42

36Department of Pediatrics, University of Montreal, Montreal, Canada. 37Department of Clinical and Developmental Neuropsychology, University of Groningen, Groningen, Netherlands. 38Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, United States. 39Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States. 40Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 41Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 42Department of Neuroscience, Research Group Psychiatry, Center for Clinical Psychiatry, Leuven, Belgium.

C. Okhuijsen-Pfeifer et al.

Otsuka; is a member of the advisory board for Janssen, Otsuka; is currently participating in an international clinical trial funded by Janssen. Dr. Tiihonen reports personal fees from the Finnish Medicines Agency (Fimea), European Medicines Agency (EMA), Eli Lilly, Janssen, Lundbeck, and Otsuka; is a member of the advisory board for Lundbeck; and has participated in research projects funded by grants from Eli Lilly and Janssen to his employing institution. All other authors have declared that there are no conflicts of interest in relation to the subject of this study.

Additional Information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41398-022-01884-3.

Correspondence and requests for materials should be addressed to J. J. Luykx.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Previous presentation: The findings described in this manuscript were presented at the virtual World Congress of Psychiatric Genetics (WCPG), 2020 October 19–21.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

Group (Genetic Risk and Outcome of Psychosis) Investigators

T. van Amelsvoort36, A. A. Bartels-Velthuis11, R. Bruggeman37, W. Cahn1, S. Guloksuz11,38, L. de Haan25,26, R. S. Kahn1,39, F. Schirmbeck25,26, C. J. P. Simon11, J. van Os1, B. Z. Alizadeh40,41, J. J. Luykx1,2,3, B. P. F. Rutten11 and R. van Winkel42

36Department of Pediatrics, University of Montreal, Montreal, Canada. 37Department of Clinical and Developmental Neuropsychology, University of Groningen, Groningen, Netherlands. 38Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, United States. 39Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States. 40Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 41Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 42Department of Neuroscience, Research Group Psychiatry, Center for Clinical Psychiatry, Leuven, Belgium.